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Reply to Letter:
‘‘TheClinical Significanceof
an Elevated Postoperative
Glucose Value in
Nondiabetic Patients After
Colorectal Surgery:
Evidence for the Need for
Tight Glucose Control?’’
Reply:
T he authors thank Kazuhiro Hanazaki andcolleagues for their valued input regard-
ing our study on the significance of elevated
postoperative glucose values in nondiabetic
patients undergoing colorectal surgery. Our
study suggests that surgical outcomes are
adversely affected by transient hyperglyce-
mia even in nondiabetic patients undergoing
major colorectal operations.1 Interventional
trials examining the benefits of tight glyce-
mic control using intravenous insulin regi-
mens in surgical patients have been plagued
by sometimes unacceptably high rates of
inadvertent iatrogenic hypoglycemia exceed-
ing 15% in some studies as mentioned in their
letter. Artificial pancreas systems are
designed to automatically adjust blood glu-
cose values in real time. The synchronous
adjustment of intravenous glucose and insu-
lin rates allows the achievement of stable
glycemia in patients at need, such as those
who have undergone complete pancreatec-
tomy or with brittle diabetes. We have
ourselves followed the development of such
systems with great interest.
Hanazaki et al were able to demon-
strate the feasibility of such an artificial
pancreas system in the surgical scenario in
patients undergoing hepatic, pancreatic, and
esophageal resections, without a single epi-
sode of hyperglycemia as reported in their
study published in the American Journal of
Surgery a few months ago.2 These results are
very laudable and promising for patients in
need of stable glycemia, as such systems may
allow for an apparently risk-free tight blood
glucose control, thus eliminating the most
obvious risk of previous tight glycemic con-
trol algorithms. However, the effect of tight
glycemic control achieved by such an artifi-
cial pancreas system on the rate of infectious
complications, organ failure, or the overall
mortality in a surgical cohort has not been
previously evaluated.
Although Hanazaki and colleagues
may be able to provide outcome data from
their large experience of 305 surgical patients
undergoing major abdominal resections, the
obvious next step would be to compare out-
comes in surgical patients receiving artificial
pancreas treatment aimed at keeping perio-
perative blood glucose levels within the
physiologic range to those not receiving such
intense control. With the recent Food and
Drug Administration approval of the first
artificial pancreas system to go into clinical
use for diabetic patients in 2013,3 the way
may now be paved for such trials in surgical
and critically ill patients who will likely
benefit the most from stable euglycemia.
As our study has shown, it is not diabetics
alone who are at risk for hyperglycemia after
abdominal surgery. If the efficacy of the
artificial pancreas in maintaining euglycemia
can be demonstrated to improve outcomes
after surgery, the role of the device will likely
evolve to encompass its use in any patient
undergoing major abdominal surgery.
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